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Objective: IPX066 is an extended release carbidopa/levodopa formulation designed to rapidly attain and
maintain therapeutic plasma concentrations for a prolonged duration, allowing dosing intervals of
approximately 6 h. The objective was to assess the efﬁcacy, safety, and impact on quality of life of IPX066
in the treatment of levodopa-naive Parkinson’s disease (PD) patients.
Methods: This was a randomized, double-blind, placebo-controlled, 30-week study of 381 levodopa-
naïve patients assigned to placebo or IPX066 containing 145, 245 or 390 mg of levodopa administered
three times daily (TID). The primary efﬁcacy measure was change from Baseline in Uniﬁed Parkinson’s
Disease Rating Scale (UPDRS) activities of daily living (Part II) þ motor scores (Part III), at 30 weeks.
Secondary outcome measures included UPDRS total and subscores, patient and clinician global im-
pressions (PGI-I, CGI-I), and the Parkinson’s Disease Questionnaire (PDQ-39).
Results: All IPX066dosageswere superior toplacebothroughout the studyandat30weeks (P<0.0001). The
mean improvement inUPDRSParts IIþ III at 30weeks compared tobaselinewas11.7,12.9, and14.9points for
the three dosages and 0.6 points for placebo (P < 0.0001, all dosages). PDQ-39 total scores improved with
IPX066 (P 0.034, all dosages). Themost commonly reported adverse events with IPX066 included nausea,
dizziness, and headache. No unexpected drug-related serious adverse events were reported.
Conclusion: IPX066 provided signiﬁcant clinical beneﬁts at the three dosages tested compared to placebo
and was well tolerated in levodopa-naive PD patients. Of the dosages tested, IPX066 145 mg TID
appeared to provide the best overall balance between efﬁcacy and safety.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction PD; however, long-term use commonly results in motor ﬂuctua-Levodopa, combined with a dopa decarboxylase inhibitor such
as carbidopa or benserazide, is the most effective treatment ofr the terms of the Creative
Works License, which per-
ion in any medium, provided
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Published by Elsevier Ltd. All rightions and dyskinesia. The short half-life of levodopa is postulated to
be largely responsible for these motor complications [1]. A
controlled release formulation of carbidopa/levodopa is currently
available, but its absorption is less predictable than that of imme-
diate release levodopa and the time for a dose to take effect is
delayed compared to the immediate release formulation [2,3].
IPX066 (Impax Laboratories Inc., Hayward, CA, USA) is an
extended release capsule formulation of carbidopa/levodopa in a
1:4 ratio. IPX066 capsules contain both immediate and extended
release carbidopa/levodopa components, where extended release
components continuously release carbidopa and levodopa in the GI
tract for a prolonged duration. This formulation design allows both
rapid attainment and maintenance of therapeutic levodopa con-
centrations. A Phase 2, open-label, crossover study in 27 advancedts reserved.
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difference between IPX066 and immediate release carbidopa/
levodopa in the time to reach 50% of peak plasma concentration
(Cmax). However, plasma levodopa levels remained stable with
levodopa concentrations sustained above 50% Cmax for 4 h on
average after a single dose of IPX066 compared to 1.4 h after a
single dose of the immediate-release carbidopa/levodopa formu-
lation [4]. In addition, improvement in PD motor symptoms was
generally sustained for 6 h with IPX066, but wore off after 3 h with
immediate release carbidopa/levodopa. The levodopa bioavail-
ability of a single dose of IPX066 relative to the same dose of im-
mediate release carbidopa/levodopa was approximately 70% and
the Cmax was 30% [4]. The present study was designed to evaluate
the safety and efﬁcacy of IPX066 in levodopa-naive PD patients.
2. Methods
This trial (Impax Pharmaceuticals, USA, protocol IPX066-B08-05, clinicaltrials.gov
NCT00880620) conducted between April 2009 and October 2010 at 56 sites in North
America (United States and Canada) and Europe (Ukraine, Romania, Lithuania, Latvia,
Estonia) was conducted in accordance with the Declaration of Helsinki and Good
Clinical Practice Guidelines. Each institution conducting the trial received institu-
tional review board or ethics committee approval and all patients provided written
informed consent. See Appendix I for a list of investigators participating in the study.
2.1. Patients
Eligible patients met the United Kingdom Parkinson’s Disease Society Brain
Bank Diagnostic Criteria for PD [5]. Patients were 30 years of age at PD diag-
nosis, Hoehn and Yahr stage I, II or III [6] and levodopa naive (not exposed to
levodopa for >30 days and not within 4 weeks of enrollment). Anticholinergics,Fig. 1. Patient ﬂow. aSix patients (1 each in the Placebo and 145 mg TID group and 2 each in
discontinued participation of the study. Data from all 6 patients were included in the analyamantadine and MAO-B inhibitors were allowed but dosages had to be stable for
4 weeks prior to study entry and unchanged throughout study. Mini-Mental State
Examination was 26 [7] and the sum of Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS) [8] Part II (activities of daily living) and Part III (motor) scores was 18.
Exclusion criteria included atypical parkinsonism, females pregnant or breast-
feeding, previous neurosurgical treatment for PD, use of nonselective MAO in-
hibitors, use of dopamine agonists within 30 days of screening, inability to
tolerate a placebo regimen and history of sensitivity to carbidopa/levodopa,
treatment of psychosis with any antipsychotic, seizure, active or prior medical
conditions that would interfere with levodopa absorption, narrow-angle glau-
coma, malignant melanoma or suspicious undiagnosed skin lesion, myocardial
infarction with residual problems, abnormal kidney function, or abnormal liver
transaminase values.2.2. Design
This was amulticenter, multinational, randomized, double-blind, parallel-group,
ﬁxed-dose, placebo-controlled, 30-week study. Eligible patients were randomized
1:1:1:1 to one of four treatment groups IPX066 36.25/145mg, IPX066 61.25/245mg,
IPX066 97.50/390 mg or matching placebo, each taken three times daily, approxi-
mately every 6 h. A randomization number was generated to determine the dosing
regimen for the blinded study drug (identical, gray capsules), which was dispensed
by the investigator at each visit. Each site was issued 8 blinded kits at a time and the
kit number became the subject’s randomization number. Randomization was per-
formed by the Impax Biostatistics Department using computer generated random
allocation tables, which were sealed and maintained by the Regulatory Affairs
Department of Impax Pharmaceuticals. No unblinding was required throughout the
study. Separate randomizations were prepared for patients who had never taken PD
medications and those that had prior exposure to or currently taking allowed non-
levodopa PD medications.
During the titration period, IPX066 was initiated at 95 mg three times daily for
all 3 groups. On day 4 the dose was increased to 145 mg three times daily for all
groups. The IPX066 145 mg group remained on this dose throughout the study
(435mg/day). On day 8, the remaining groups received 195mg three times daily andthe 245 mg TID and 390 mg TID groups) at one site were discontinued because the site
sis.
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remained on this dose throughout the study (735 mg/day). On day 22, the dose was
increased to 390 mg for the IPX066 390 mg group and this dose was maintained
throughout the study (1170 mg/day). Placebo patients were administered matching
numbers of identical-looking capsules throughout the study. The clinical status of
each subject was monitored by phone calls approximately every three days for the
ﬁrst four weeks to evaluate the subject’s ability to tolerate the study medication.
Patients who could not progress to the next titration level or required rescue
medication were not allowed to continue the study. Patients were evaluated at
baseline and weeks 4, 9, 16, 23, and 30. Patients who successfully completed the
study were eligible for a 9-month, open-label study (protocol IPX066-B09-03;
clinicaltrials.gov NCT01096186).2.3. Outcome measures
The primary outcome of the study was the change from baseline to week 30 in
the sum of UPDRS Parts II and III [8] for the intent to treat (ITT) population (all
patients receiving at least one dose of study drug and providing any outcome
data). All raters were trained and certiﬁed to administer the UPDRS. Secondary
outcome measures included change from Baseline in UPDRS Parts I (mentation), II,
III, IV (motor complications), II þ III, I þ II þ III and I þ II þ III þ IV scores, patient
and clinician global impression of improvement (PGI-I/CGI-I), and PDQ-39
assessment of quality of life [9] at each study visit. A responder analysis was
also conducted.2.4. Safety measures
Safety assessments included adverse events (AEs), physical examinations,
concomitant medications, vital signs, electrocardiograms, clinical laboratory tests,
and the Beck Depression Inventory-II (BDI-II).Table 1
Demographics and Parkinson’s disease characteristics by treatment group at Base-
line (safety population; mean (SD)).
Characteristic Placebo
(n ¼ 92)
145 mg TID
(n ¼ 87)
245 mg TID
(n ¼ 104)
390 mg TID
(n ¼ 98)
Age (years) 65.4 (9.4) 63.8 (9.8) 65.2 (9.7) 64.8 (9.3)
Male gender (#,%) 52 (56.5) 47 (54.0) 59 (56.7) 54 (55.1)
White (#,%) 90 (98) 87 (100) 102 (98) 96 (98)
Black/African
American (#,%)
0 0 2 (1.9%) 0
Asian (#,%) 1 (1.1) 0 0 1 (1.0)
Other race (#,%) 1 (1.1) 0 0 1 (1.0)
Weight (kg) 77.9 (15.3) 77.8 (15.2) 81.2 (16.1) 77.3 (15.5)
Body mass
index (kg/m2)
27.4 (4.6) 27.2 (4.3) 28.3 (4.6) 27.4 (5.1)
MMSE scores 28.9 (1.2) 29.0 (1.3) 28.7 (1.2) 28.9 (1.2)
BDI-II scores 10.7 (7.9) 11.4 (8.2) 11.0 (8.2) 10.7 (9.3)
Total PDQ-39 score 24.0 (15.5) 26.0 (16.9) 25.2 (18.6) 25.1 (17.1)
Age at PD
onset (years)
63.7 (9.5) 61.7 (10.7) 63.6 (10.4) 63.0 (9.4)
Duration of
PD (years)
1.8 (2.0) 2.3 (3.1) 1.8 (1.8) 2.0 (2.3)2.5. Statistical analyses
A sample size of 75 patients per group at Week 30 was determined to have
approximately 85% power to detect a mean difference of 6 units in the sum of UPDRS
Parts II and III between IPX066 and placebo, assuming a standard deviation of 12
units based on a previous study of levodopa-naive PD patients [10].
Demographics and Baseline PD characteristics were summarized and compared.
The primary outcome was analyzed assuming a three-factor model with treatment,
strata (previous use of PD medications or no PD medication), and region (North
America, Europe) being the main effects. Fisher’s least signiﬁcant difference
approach was used and if the overall treatment effect was signiﬁcant (P< 0.05), pair
wise comparisons were conducted. An analysis of covariance of each measure was
also used with the Baseline measure being the covariate. A sensitivity analysis of the
primary outcome using Dunnett’s procedurewas also performed. Data from patients
who withdrew before completing the Week 30 visit, received at least one dose of
study medication and had at least one efﬁcacy assessment post-Baseline were
included in the efﬁcacy analyses using a last observation carried forward approach.
Changes from Baseline at Weeks 4, 9, 16, and 23 were analyzed in a similar manner.
For UPDRS and PDQ-39 secondary endpoint variables, similar analyses were con-
ducted. Categorical variables were examined using CochraneManteleHaenszel chi-
squared techniques. The safety analysis included all patients randomized who
received at least one dose of study medication.
A responder analysis was conducted. A responder was deﬁned as any subject
with a mean improvement of at least 25% on the sum of UPDRS Parts II and III.
Sensitivity analyses were also conducted using 20, 30 and 40% as additional mea-
sures of responders. CochraneManteleHaenszel chi-squared techniques were used
for the responder analyses. Patients terminated early were considered non-
responders at the study endpoint and any visits that were not completed.UPDRS Part I 1.5 (1.5) 1.6 (1.4) 1.7 (1.5) 1.7 (1.6)
UPDRS Part II 10.2 (4.5) 10.3 (4.5) 10.3 (5.0) 9.9 (4.4)
UPDRS Part III 26.1 (9.0) 25.9 (10.6) 27.8 (12.2) 26.4 (10.1)
UPDRS Part
II þ III
36.3 (11.9) 36.1 (13.6) 38.1 (15.6) 36.3 (13.0)
UPDRS Part IV 0.4 (0.9) 0.5 (1.2) 0.4 (1.1) 0.5 (1.2)
Hoehn and Yahr
Stage I (#,%)
7 (7.6) 6 (6.9) 13 (12.5) 14 (14.3)
Hoehn and Yahr
Stage II (#,%)
69 (75.0) 62 (71.3) 65 (62.5) 62 (63.3)
Hoehn and Yahr
Stage III (#,%)
16 (17.4) 19 (21.8) 26 (25.0) 22 (22.4)
TID e three times daily; MMSE e Mini-Mental State Examination; BDI-II e Beck
Depression Inventory-II; PDQ-39 e Parkinson’s Disease Questionnaire quality of life
assessment; PD e Parkinson’s disease; UPDRS e Uniﬁed Parkinson’s Disease Rating
Scale (Part Iementation; Part IIe activities of daily living; Part IIIemotor; Part IVe
complications of therapy).3. Results
Between April 2009 and October 2010, 381 PD patients were
randomized and received at least one dose of study medication
(safety population); 171 were from North America and 210 from
Europe. The study completion rate was 78.7% (300 of 381). The
most common reason for discontinuation was AEs (10.2%). Fig. 1
depicts the subject disposition. Demographics and PD characteris-
tics of the safety population at Baseline are shown in Table 1. There
were no signiﬁcant differences in Baseline measures across treat-
ment groups (P > 0.3475 for all measures) and patients who used
non-levodopa PD medications were equally distributed across
treatment groups.3.1. Efﬁcacy
There were 361 patients available for the UPDRS and PDQ-39
outcome measures (4 patients had no post-Baseline visits and in
16 patients the early termination visit was more than 3 days after
the last dose of study drug and no other post-Baseline visits were
available). The primary outcome, change in UPDRS Parts II þ III
from Baseline to the end of the study, Week 30 or ﬁnal visit carried
forward, was signiﬁcant for all dosages of IPX066 compared to
placebo (P < 0.0001; Table 2; Fig. 2). The mean improvement from
Baseline for each of the IPX066 treatments was 11.7 (145 mg TID),
12.9 (245 mg TID), and 14.9 (390 mg TID) points, compared with a
mean improvement of 0.6 points for placebo. The results were
similar (P  0.0001) for each of the IPX066 treatments compared
with placebo at all study visits, indicating that the treatment effect
was evident throughout the 30 weeks (Fig. 2). While there were no
signiﬁcant differences between the active treatments, the IPX066
390 mg TID group had the greatest mean improvement in UPDRS
score.
Secondary efﬁcacy endpoints, including change from Baseline in
UPDRS Parts I þ II þ III and in individual UPDRS subscores at the
end of the study (Table 2) and at all study visits, were signiﬁcant
(P < 0.05) for all IPX066 dosages compared to placebo. UPDRS Part
IV (complications) did not change signiﬁcantly compared to pla-
cebo. The Total PDQ-39 and activities of daily living scores at the
end of study visit for all IPX066 groups had signiﬁcant improve-
ments from Baseline compared to aworsening in the placebo group
(Table 2).
For both the PGI-I and CGI-I scales at the end of study visit
(n ¼ 377), each of the three active treatments was statistically
Table 2
Change from Baseline to end of study (Week 30 or last visit carried forward) for primary and secondary efﬁcacy outcomes (P-values and 95% conﬁdence intervals compared to
placebo).
Efﬁcacy measure Placebo (n ¼ 90) 145 mg TID (n ¼ 82) 245 mg TID (n ¼ 99) 390 mg TID (n ¼ 90)
UPDRS Parts II þ III 0.6 11.7; P < 0.0001; (15.1, 7.1) 12.9; P < 0.0001; (16.2, 8.6) 14.9; P < 0.0001; (18.3, 10.5)
UPDRS Parts I þ II þ III 0.4 12.1; P < 0.0001; (15.8, 7.5) 13.2; P < 0.0001; (16.8, 8.8) 15.2; P < 0.0001; (18.9, 10.8)
UPDRS I 0.2 0.4; P ¼ 0.01; (1.0, 0.1) 0.3; P ¼ 0.03; (0.9, 0.0) 0.3; P ¼ 0.03; (0.9, 0.0)
UPDRS II 0.2 2.8; P < 0.0001; (4.4, 1.4) 3.1; P < 0.0001; (4.7, 1.9) 3.9; P < 0.0001; (5.5, 2.6)
UPDRS III 0.7 8.9; P < 0.0001; (11.2, 5.2) 9.8; P < 0.0001; (11.9, 6.2) 11.0; P < 0.0001; (13.2, 7.4)
UPDRS IV 0.1 0.1; P ¼ 0.53; (0.07, 0.2) 0.3; P ¼ 0.55; (0.2, 0.6) 0.3; P ¼ 0.56; (0.2, 0.6)
PDQ-39 mobility 0.9 4.0; P ¼ 0.14; (11.2, 1.4) 3.6; P ¼ 0.17; (10.6, 1.5) 6.8; P ¼ 0.01; (13.9, 1.5)
PDQ-39 activities of daily living 2.8 7.9; P ¼ 0.0005; (17.4, 3.9) 8.8; P < 0.0001; (18.0, 5.1) 11.5; P < 0.0001; (20.9, 7.7)
PDQ-39 emotional well being 1.2 6.1; P ¼ 0.01; (13.3, 1.2) 4.0; P ¼ 0.09; (_10.9, 0.6) 5.2; P ¼ 0.03; (12.2, 0.5)
PDQ-39 stigma 0.8 7.2; P ¼ 0.046; (12.9, 0.1) 6.0; P ¼ 0.11 (11.4, 0.9) 10.4; P ¼ 0.001; (15.6, 3.3)
PDQ-39 social support 0.7 1.0; P ¼ 1.0; (5.7, 5.2) 2.2; P ¼ 0.84; (6.7, 3.7) 1.3; P ¼ 1.0; (5.8, 4.7)
PDQ-39 cognition 0 2.4; P ¼ 0.54; (7.5, 2.7) 2.2; P ¼ 0.58; (2.7, 7.1) 1.3; P ¼ 0.88; (3.7, 6.3)
PDQ-39 communication 0.6 0.2; P ¼ 0.97; (6.6, 4.9) 1.1; P ¼ 0.81; (7.2, 3.8) 1.2; P ¼ 0.77; (7.5, 3.8)
PDQ-39 bodily discomfort 1.8 1.3; P ¼ 0.99; (6.5, 7.5) 2.8; P ¼ 0.98; (7.6, 5.8) 5.9; P ¼ 0.38; (10.9, 2.8)
PDQ-39 total 0.6 4.4; P ¼ 0.02; (9.3, 0.6) 3.8; P ¼ 0.03; (8.5, 0.3) 6.0; P ¼ 0.0008; (10.7, 2.3)
Responder rate 20% (%) 22.8 62.1a 72.1a 70.4a
Responder rate 25% (%) 14.1 57.5a 67.3a 65.3a
Responder rate 30% (%) 12.0 50.6a 53.8a 58.2a
Responder rate 40% (%) 7.6 34.5a 37.5a 51.0a
aP < 0.0001, Chi Square Test vs. Placebo.
TID e three times daily; UPDRS e Uniﬁed Parkinson’s Disease Rating Scale (Part I e mentation; Part II e activities of daily living; Part III e motor; Part IV e complications of
therapy); PDQ-39 e Parkinson’s Disease Questionnaire quality of life assessment; for all measures lower scores represent better scores.
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tients reporting improvement ranged from 70.3% to 73.5% for the
active treatments compared to 33.7% for placebo, and the percent of
patients reported by clinicians to have improved using the same
scale ranged from 70.8% to 72.6% for the active treatments
compared to 27.2% for placebo. The results of the responder ana-
lyses also showed that all three IPX066 groups had signiﬁcantly
more patients with at least 25% improvement over Baseline in
UPDRS Parts II and III at the end of the study (Table 2).
3.2. Safety results
Approximately two-thirds (68.5%) of the 381 patients evaluable
for safety experienced AEs, and the overall AE rate in the 145 mg
TID group (56.3%) was notably lower than that of the placebo group
(72.8%) and the 245 mg TID (72.1%) and 390 mg TID (71.4%) groups.
The most common AEs (i.e., occurring in >5% of patients in any
treatment group) are shown in Table 3. Nausea, headache, dizziness
and insomnia were the most common AEs overall. Aside from
depression, which occurred in a higher proportion of patients in theFig. 2. Mean (SE) UPDRS Part II þ III over time in levodopa-naive Parkinson’s disease patien
compared to placebo was statistically different, P < 0.0001.placebo group than in the IPX066 groups, most of the AEs clustered
in the two higher IPX066 dose groups. None of 14 serious AEs were
attributed to study treatment, and the numbers of patients expe-
riencing serious AEs were similar across all treatment groups. One
death due to non-Hodgkin’s lymphoma occurred during the titra-
tion period. Overall, 39 patients (10.2%) experienced AEs that
contributed to early discontinuation of treatment, with a smaller
percentage of patients in the 145 mg TID and placebo groups (5.7%
and 4.3%, respectively) than in the 245 mg TID and 390 mg TID
groups (14.4% and 15.3%, respectively). Adverse events contributing
to early discontinuation occurring in at least two patients in any
treatment group were nausea, dizziness, vomiting, diarrhea and
dyskinesia. Differences among the treatment groups in laboratory
test results, electrocardiograms, vital signs and the BDI-II were
unremarkable.
4. Discussion
This study demonstrated that IPX066 at dosages with 145, 245
and 390 mg of levodopa three times daily has an acceptable safetyts (APEX-PD Study). Each treatment group at all study visits and at the end of the study
Table 3
Adverse events occurring in greater than 5% of any treatment group. Summary of Adverse Events Occurring in at least 5% of Patients in any Treatment Group in Study IPX066-
B08-05 (Randomized Patients).
Adverse event Number of patients (%)
Placebo (N ¼ 92) IPX066 LD dose group Total (N ¼ 381)
145 mg (N ¼ 87) 245 mg (N ¼ 104) 390 mg (N ¼ 98)
Nausea 8 (8.7) 12 (13.8) 20 (19.2) 20 (20.4) 60 (15.7)
Headache 10 (10.9) 6 (6.9) 13 (12.5) 17 (17.3) 46 (12.1)
Dizziness 5 (5.4) 8 (9.2) 20 (19.2) 12 (12.2) 45 (11.8)
Insomnia 3 (3.3) 2 (2.3) 9 (8.7) 6 (6.1) 20 (5.2)
Abnormal dreams 0 2 (2.3) 6 (5.8) 5 (5.1) 13 (3.4)
Dry mouth 1 (1.1) 3 (3.4) 2 (1.9) 7 (7.1) 13 (3.4)
Vomiting 3 (3.3) 2 (2.3) 2 (1.9) 5 (5.1) 12 (3.1)
Constipation 1 (1.1) 2 (2.3) 6 (5.8) 2 (2.0) 11 (2.9)
Dyskinesia 0 2 (2.3) 4 (3.8) 5 (5.1) 11 (2.9)
Anxiety 0 2 (2.3) 3 (2.9) 5 (5.1) 10 (2.6)
Depression 5 (5.4) 1 (1.1) 2 (1.9) 2 (2.0) 10 (2.6)
Orthostatic hypotension 1 (1.1) 1 (1.1) 1 (1.0) 5 (5.1) 8 (2.1)
R. Pahwa et al. / Parkinsonism and Related Disorders 20 (2014) 142e148146proﬁle and is effective in controlling PD features in levodopa-naive
PD patients as measured by UPDRS, PDQ-39 and patient and
clinician global impressions. The lowest dosage tested, 145 mg of
levodopa three times daily appeared to provide the best balance
between efﬁcacy and safety. However, this ﬁxed-dose study did not
identify the minimally effective or no effect dose; therefore in
clinical practice, it is possible that dosages lower than 145 three
times daily may provide beneﬁt. Improvements were evident at
Week 4 (ﬁrst post-Baseline visit) and continued throughout the
study (Fig. 2).
Due to the sustained-release nature of the IPX066 formulation,
the levodopa bioavailability of IPX066 is approximately 70% for area
under the curve (AUC) and 30% for Cmax relative to that of imme-
diate release carbidopa/levodopa [4]. Therefore, the 145, 245 and
390 mg of IPX066 three times daily regimens tested in this study
are roughly equivalent to daily dosages of 300, 500 and 800 mg of
the immediate release formulation of levodopa in terms of AUC and
to 45 mg, 75 mg, and 120 mg of levodopa three times daily in terms
of Cmax [4].
The current study design is similar to the Earlier versus Later
Levodopa Therapy in Parkinson Disease (ELLDOPA) study [11]. As in
ELLDOPA, which examined the effects of immediate release carbi-
dopa/levodopa, all dosages of IPX066 were superior to placebo in
controlling the motor symptoms of PD as measured by the UPDRS.
In the ELLDOPA study, UPDRS Part III (motor) scores improved 3
points (150 mg/day), 5.9 points (300 mg/day) and 7.1 points
(600 mg/day) at 24 weeks compared to Baseline [12], while in the
present study, UPDRS Part III improved 8.9 points (145 mg TID), 9.8
points (245 mg TID) and 11.0 points (390 mg TID) at 30 weeks
compared to Baseline. However, in the ELLDOPA study the mean
disease duration ranged from 5.3 to 7.6 months and the Baseline
UPDRS motor scores ranged from 18.6 to 20.5, whereas in the
current study mean disease duration ranged from 1.8 to 2.3 years
and Baseline UPDRS motor scores ranged from 25.9 to 27.8, limiting
direct comparisons between the two studies. In addition, in the
ELLDOPA study, signiﬁcantly more dyskinesia was seen with the
highest levodopa dose (600 mg/day, 16.5%) compared to the other
treatment groups. In contrast, in the current study, dyskinesia was
similar across the three doses with the highest IPX066 dose,
comparable to approximately 800 mg/day of immediate release
levodopa in terms of AUC, with dyskinesia in only 5.1% of subjects.
The FIRST-STEP trial was conducted to determine if adding
entacapone, a catechol-O-methyl transferase inhibitor that in-
creases levodopa AUC 35e40% without affecting levodopa Cmax, to
carbidopa/levodopa would provide greater symptomatic beneﬁt
without increasing the development of dyskinesia in levodopa-naive PD patients compared to immediate release carbidopa/levo-
dopa [13]. After 39 weeks, UPDRS Parts II þ III scores were
improved 8.5 points with carbidopa/levodopa (25/100 TID)
compared to Baseline. In the present study, IPX066 (145 mg TID)
resulted in an 11.7-point change in UPDRS IIþ III scores at 30 weeks
compared to Baseline. In the FIRST-STEP study the mean Baseline
UPDRS Part II þ III score was 34.3 and patients had a mean disease
duration of 1.2 years and a mean age of 64.8 years. In addition, in
the FIRST-STEP study, 7.4% taking carbidopa/levodopa developed
dyskinesia, compared to 2.3% in the current study with IPX066
145 mg three times daily and 5.1% with the highest dose of IPX066.
Finally, in the Ropinirole 056 study [14], ropinirole and carbi-
dopa/levodopa were compared in early PD patients. The patient
population in the carbidopa/levodopa arm of the Ropinirole 056
study was similar to the current study with a mean disease dura-
tion of 2.4 years, a mean age of 63 years and a mean UPDRS motor
score of 21.7 points. Results of the 6-month interim analysis
revealed an 8.4-point improvement in UPDRS motor scores in the
carbidopa/levodopa arm (mean 464 mg/day), which is similar to
the 8.9-point improvement seen in the 145 mg three times daily
arm of the current study. However, dyskinesia was reported in
11.2% of the carbidopa/levodopa arm of the Ropinirole 056 study
compared to 2.3% in the current study (145 mg TID).
Of the 381 patients randomized, 300 patients completed the
trial. The discontinuation rates for the two higher doses of IPX066
(245 and 390 mg TID) and placebo were similar (range, 20e25%),
whereas the rate for the 145 mg TID group was lower (17%). AEs
were the predominant reason for discontinuation in the two higher
IPX066 dose groups, whereas the predominant reason in the pla-
cebo group was lack of efﬁcacy. These results are not unexpected,
because placebo should not be effective, and the ﬁxed-dose, forced-
titration nature of the trial requiring levodopa-naive patients to
reach relatively high doses of levodopa (equivalent to daily dosages
of 500 and 800 mg in 14 and 21 days) in a short period of time with
no option to lower the dose may have contributed to the dropouts
due to safety issues. Adverse events resulting in early termination
were, in general, typical dopaminergic events. The fact that esca-
lation to the assigned dose was fairly rapid in this study, i.e., 3
weeks compared with 9 weeks for the ELLDOPA study, may also
have contributed to early discontinuation due to AEs. In general, the
most common AEs were comparable to those seen in other studies
examining various oral levodopa formulations [9,13e15].
In summary, each of the three active dosages of IPX066 was
consistently effective across all efﬁcacymeasures used in this study.
This is not unexpected given that IPX066 is a levodopa preparation.
Although this study did not establish a minimally effective or no
R. Pahwa et al. / Parkinsonism and Related Disorders 20 (2014) 142e148 147effect dose, results were highly signiﬁcant, clinically robust, and
were evident from the ﬁrst post-Baseline visit throughout the end
of the study. AEs were generally typical for a dopaminergic agent,
with higher dosages resulting in a greater number of AEs. Taking
into account both efﬁcacy and safety results, this study demon-
strated that all three IPX066 regimens are effective; however,
higher dosages were not as well tolerated in this levodopa-naive PD
population.
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